Skip to main content
PREDILIFE logo

PREDILIFE — Investor Relations & Filings

Ticker · ALPRE ISIN · FR0010169920 LEI · 9695006IK5NBKHQU9116 PA Human health and social work activities
Open in API
Filings indexed 150 across all filing types
Latest filing 2026-04-07 Regulatory Filings
Country FR France
Listing PA ALPRE

About PREDILIFE

https://www.predilife.com/en/

PREDILIFE specializes in predictive medicine, developing solutions to assess an individual's risk of developing major diseases. The company's approach integrates medical data, such as genetic testing and imaging, with artificial intelligence and mathematical models to create personalized risk profiles. Its primary offerings are predictive health check-ups, including a specialized test for assessing the 5-year risk of breast cancer (MammoRisk®) and a multi-condition check-up that evaluates the risk for several common cancers (lung, prostate, colorectal, melanoma) and cardiovascular disease. Based on these risk profiles, PREDILIFE provides personalized follow-up and preventive recommendations. The company offers its end-to-end solution, which includes remote consultations, to businesses, insurers, and healthcare professionals to facilitate wider access to preventive care.

Recent filings

Filing Released Lang Actions
Predilife détaille sa stratégie industrielle et financière
Regulatory Filings Classification · 1% confidence The document is a press release (“communiqué de presse”) detailing Predilife’s industrial and financial strategy, pipeline assets, cash‐burn outlook, and future publication dates for its 2025 results and annual report. It does not contain actual financial results (so it is not an Earnings Release or Interim/Quarterly Report), nor does it describe a closed financing (so not a Capital/Financing Update), board changes, voting results, or other narrowly defined events. It primarily serves as a general corporate/regulatory announcement. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2026-04-07 French
Retour de la FDA dans le cadre de la soumission de DenSeeRisk, dispositif médical combinant MammoRisk et analyse de mammographies par IA
Regulatory Filings Classification · 1% confidence The document is a press release from Predilife announcing regulatory progress with the FDA regarding their medical device 'DenSeeRisk'. It details the company's interaction with the FDA, the submission process, and the strategic context of the product. As it is a corporate announcement regarding business operations and regulatory status rather than a formal financial report, a proxy statement, or a specific governance filing, it falls under the general category of regulatory announcements.
2026-03-02 French
Bilan semestriel au 31/12/2025 du contrat de liquidité PREDILIFE
Transaction in Own Shares Classification · 1% confidence The document is a press release titled 'Bilan semestriel au 31/12/2025 du contrat de liquidité PREDILIFE'. It provides a detailed report on the company's liquidity contract, including the number of shares held, cash balance, and a comprehensive table of daily buy/sell transactions for the second half of 2025. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Growth to report on their share repurchase/liquidity programs. Since it is a specific report on the company's own share transactions, it falls under the 'Transaction in Own Shares' category.
2026-01-16 French
Une avancée scientifique majeure contre le cancer du sein - Validation de la stratégie globale de MammoRisk
Regulatory Filings Classification · 1% confidence The document is a press release issued by PREDILIFE regarding scientific validation of their MammoRisk product based on external clinical study results. It does not report financial results, dividends, or governance changes, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding business developments and product validation that does not fit into specific categories like M&A or share issues, it falls under the general regulatory announcement category.
2025-12-17 French
PREDILIFE ANNONCE LA REALISATION D'UNE LEVEE DE FONDS D'ENVIRON 900.000 EUROS DANS LE CADRE DE SON OFFRE AU PUBLIC D'OBLIGATIONS CONVERTIBLES A 8,5% PAR AN REMBOURSABLES IN FINE EN INTEGRALITÉ EN ESPÈ
Capital/Financing Update Classification · 1% confidence The document is a press release from Predilife announcing the successful completion of a fundraising event through the issuance of convertible bonds (OCEANE). It details the amount raised, the purpose of the funds, the impact on capital structure, and dilution effects. This falls under the category of company financing and capital structure updates.
2025-12-10 French
PREDILIFE LANCE UNE ÉMISSION D'OBLIGATIONS CONVERTIBLES DE 1,5M EUR A UN TAUX DE 8,5% PAR AN SUR 5 ANS REMBOURSABLES IN FINE EN INTEGRALITÉ EN ESPÈCES OU EN ACTIONS POUR RENFORCER SES INVESTISSEMENTS
Capital/Financing Update Classification · 1% confidence The document is a press release from Predilife announcing the launch of a public offering of convertible bonds (OCEANE). It details the financial terms, the purpose of the capital raise (investing in AI and development), the legal framework, and the dilution impact on shareholders. This falls squarely under the definition of a Capital/Financing Update (CAP), as it describes a specific fundraising activity and changes to the company's capital structure.
2025-11-17 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.